196 related articles for article (PubMed ID: 24199835)
1. Incentives for new antibiotics: the Options Market for Antibiotics (OMA) model.
Brogan DM; Mossialos E
Global Health; 2013 Nov; 9():58. PubMed ID: 24199835
[TBL] [Abstract][Full Text] [Related]
2. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
Brogan DM; Mossialos E
Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
[TBL] [Abstract][Full Text] [Related]
3. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics.
Renwick MJ; Brogan DM; Mossialos E
J Antibiot (Tokyo); 2016 Feb; 69(2):73-88. PubMed ID: 26464014
[TBL] [Abstract][Full Text] [Related]
4. [Lack of incentives for the development of innovative antibiotics-analysis of market and time constraints].
Müller R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jun; 63(6):771-776. PubMed ID: 32410054
[TBL] [Abstract][Full Text] [Related]
5. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
[TBL] [Abstract][Full Text] [Related]
6. Implementation of a Market Entry Reward within the United States.
Daniel GW; Schneider M; Lopez MH; McClellan MB
J Law Med Ethics; 2018 Jun; 46(1_suppl):50-58. PubMed ID: 30146957
[TBL] [Abstract][Full Text] [Related]
7. Time for a change in how new antibiotics are reimbursed: Development of an insurance framework for funding new antibiotics based on a policy of risk mitigation.
Towse A; Hoyle CK; Goodall J; Hirsch M; Mestre-Ferrandiz J; Rex JH
Health Policy; 2017 Oct; 121(10):1025-1030. PubMed ID: 28888660
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics in late clinical development.
Fernandes P; Martens E
Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
10. Learning from our mistakes: using key opportunities to remove the perverse incentives that help drive antibiotic resistance.
Edwards SE; Morel CM
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):685-692. PubMed ID: 31847613
[No Abstract] [Full Text] [Related]
11. Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal.
Tarín-Pelló A; Suay-García B; Pérez-Gracia MT
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1095-1108. PubMed ID: 35576494
[TBL] [Abstract][Full Text] [Related]
12. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
[TBL] [Abstract][Full Text] [Related]
13. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
14. Countries mull over incentives for developing antibiotics.
Anderson T
Lancet; 2016 May; 387(10031):1894-5. PubMed ID: 27203638
[No Abstract] [Full Text] [Related]
15. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
[TBL] [Abstract][Full Text] [Related]
16. Market concentration of new antibiotic sales.
Rahman S; Lindahl O; Morel CM; Hollis A
J Antibiot (Tokyo); 2021 Jun; 74(6):421-423. PubMed ID: 33664435
[TBL] [Abstract][Full Text] [Related]
17. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus.
Morel CM; Lindahl O; Harbarth S; de Kraker MEA; Edwards S; Hollis A
J Antibiot (Tokyo); 2020 Jul; 73(7):421-428. PubMed ID: 32203126
[TBL] [Abstract][Full Text] [Related]
18. Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy.
Outterson K; McDonnell A
Health Aff (Millwood); 2016 May; 35(5):784-90. PubMed ID: 27140983
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
